Nanodisc Platform for 19F-MRI
用于 19F-MRI 的 Nanodisc 平台
基本信息
- 批准号:10746675
- 负责人:
- 金额:$ 27.29万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-07-11 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:AffectAnimalsApolipoproteinsAreaBiodistributionBiologicalBiological MarkersBiopsyBreast Cancer ModelCell Culture TechniquesCell TherapyCellsCharacteristicsChargeCholesterolCirculationClinicalComplexContrast MediaDetectionDevelopmentDiameterDimensionsDiseaseDisease MarkerDrug Delivery SystemsEnvironmentFluorineFluorocarbonsFormulationFoundationsGadoliniumGoalsHepatocyteHigh Density LipoproteinsHistologyHydrophobicityImageImmuneImmunologic SurveillanceInvestigationLabelLipid BilayersLipidsLiquid substanceLiverLongitudinal StudiesMacrophageMagnetic Resonance ImagingMembraneMethodsMicrofluidicsModalityModelingMonitoring Clinical TrialsMusNoiseOilsPhagocytesPhagocytosisPositioning AttributePrecision therapeuticsProductionProtonsRadiation therapyRadioisotopesReagentReticuloendothelial SystemRiskSamplingScaffolding ProteinSignal TransductionSpecificityStructureSurfaceSystemT-LymphocyteTechniquesTechnologyTestingTherapeuticThickTissuesToxic effectToxicity TestsTumor MarkersTumor-associated macrophagesVaccinesValidationWaterWorkaqueouscellular imagingchelationclinical imagingdetection sensitivitydisease diagnosisfluorophoreimaging agentimaging biomarkerimaging probeimaging studyimprovedinnovationinterestmanufacturing scale-upmimeticsmolecular imagingmouse modelnanodisc technologynanodisknanoemulsionnanomaterialsnanoparticlenanosystemsnew technologynovelnuclear imagingparticlephysical propertypilot testscale upspecific biomarkersstoichiometrysuccesssurfactanttargeted biomarkerultrasounduptake
项目摘要
19F MRI, has shown promising success in clinical trials for monitoring cell therapy, where small groups of
cells, showing poor contrast in 1H-MRI (Magnetic Resonance Imaging), are easily tracked using 19F-MRI.1
Contrast is provided by nanoemulsions of perfluorocarbon (PFC) oils pre-loaded into cells. A major advantage
of 19F-MRI is that lack of natural fluorine in the body allows for very high contrast-to-noise for 19F-MRI
compared to 1H-MRI.2 Use of 19F-MRI in molecular imaging, by targeting specific biomarkers, is of great
interest, but the development of probes for these applications has been an elusive goal. Typical synthetic
methods produce relatively large particles, > 150 nm, which induce nonspecific uptake by phagocytic cells.
While avid nonspecific uptake is advantageous for labeling T cells and other immune cells ex vivo, it is a
decided limitation for imaging of biomarkers as it can create high background signal in the inflamed tissues
characteristic in many diseases. 19F MRI should be an excellent platform for biomarker detection but there is a
critical unmet need for suitable 19F MRI contrast agents that avoid nonspecific immune cell surveillance.
Ideally, contrast agents need to be<100 nm to avoid nonspecific uptake. We propose exploratory studies to
develop innovative new 19F MRI contrast agents based on nanodiscs. Nanodiscs are < 50 nm in size, avoid
liver clearance, and escape immune surveillance. We hypothesize that nanodiscs, which are structurally similar
to high density lipoproteins that carry cholesterol in a hydrophobic core, may be ideal for carrying hydrophobic
perfluorocarbons. Our aims are to explore synthetic parameters in benchtop (Aim 1) and microfluidic (Aim 2)
approaches to optimize loading of perfluorocarbons into nanodiscs. In each aim we will systematically
investigate variables that influence nanodisc size and perfluorocarbon loading. New nanodiscs will be
characterized for physical properties such composition and dimensions, and the top 3 products from each Aim
will be evaluated for lack of toxicity and biodistribution in a mouse model. The leading nanodiscs will be
modified for targeting CD204, a biomarker for tumor associated macrophages, and tested in a mouse breast
cancer model. We are team composed of contrast agent (UCD) and nanodisc (LLNL) experts who are ideally
positioned and well-equipped to carry out the proposed aims. The success of this project would add novel
nanodiscs materials with the potential not only for targeted 19F MR molecular imaging, but for applications in
photoacoustic, and radiotherapy, and tracking drug delivery.
19 F MRI在监测细胞治疗的临床试验中显示出有希望的成功,其中小群体的
细胞在1H-MRI(磁共振成像)中显示出较差的对比度,使用19 F-MRI很容易跟踪。
对比度是由预先装入细胞的全氟化碳(PFC)油的纳米乳液提供的。一个主要优点
19 F-MRI的另一个优点是,人体内缺乏天然氟,这使得19 F-MRI具有非常高的噪声对比度
与1H-MRI相比。2通过靶向特定的生物标志物,19 F-MRI在分子成像中的应用具有很大的优势。
虽然这些应用的探针的开发一直是一个难以实现的目标。典型的合成
方法产生相对大的颗粒,> 150 nm,其诱导吞噬细胞的非特异性摄取。
虽然亲和非特异性摄取对于离体标记T细胞和其他免疫细胞是有利的,但它是一种非特异性摄取。
生物标志物成像的决定性限制,因为它可以在发炎组织中产生高背景信号
许多疾病的特征。19 F MRI应该是一个很好的生物标志物检测平台,但有一个
对避免非特异性免疫细胞监视的合适19 F MRI造影剂的关键未满足需求。
理想情况下,造影剂需要<100 nm以避免非特异性摄取。我们建议进行探索性研究,
开发基于纳米盘的创新性新型19 F MRI造影剂。纳米盘尺寸< 50 nm,避免
肝脏清除和逃避免疫监视我们假设结构相似的纳米盘
与在疏水核中携带胆固醇的高密度脂蛋白结合,可能是携带疏水核的理想选择。
全氟化碳。我们的目标是探索在台式(目标1)和微流控(目标2)的合成参数
优化将全氟化碳加载到纳米盘中的方法。在每个目标中,我们将系统地
研究影响纳米盘尺寸和全氟化碳负载的变量。新的纳米盘将
表征组成和尺寸等物理性能,以及每个目标的前3种产品
将在小鼠模型中评价无毒性和生物分布。领先的纳米盘将是
针对肿瘤相关巨噬细胞的生物标志物CD 204进行修饰,并在小鼠乳腺中进行测试。
癌症模型我们是由造影剂(UCD)和纳米盘(LLNL)专家组成的团队,他们理想地
有能力和有条件实现所提出的目标。该项目的成功将增加新的
纳米盘材料不仅有潜力用于靶向19 F MR分子成像,而且有潜力应用于
光声、放射治疗和跟踪药物输送。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Nicholas Oliver Fischer其他文献
Nicholas Oliver Fischer的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
The earliest exploration of land by animals: from trace fossils to numerical analyses
动物对陆地的最早探索:从痕迹化石到数值分析
- 批准号:
EP/Z000920/1 - 财政年份:2025
- 资助金额:
$ 27.29万 - 项目类别:
Fellowship
Animals and geopolitics in South Asian borderlands
南亚边境地区的动物和地缘政治
- 批准号:
FT230100276 - 财政年份:2024
- 资助金额:
$ 27.29万 - 项目类别:
ARC Future Fellowships
The function of the RNA methylome in animals
RNA甲基化组在动物中的功能
- 批准号:
MR/X024261/1 - 财政年份:2024
- 资助金额:
$ 27.29万 - 项目类别:
Fellowship
Ecological and phylogenomic insights into infectious diseases in animals
对动物传染病的生态学和系统发育学见解
- 批准号:
DE240100388 - 财政年份:2024
- 资助金额:
$ 27.29万 - 项目类别:
Discovery Early Career Researcher Award
Zootropolis: Multi-species archaeological, ecological and historical approaches to animals in Medieval urban Scotland
Zootropolis:苏格兰中世纪城市动物的多物种考古、生态和历史方法
- 批准号:
2889694 - 财政年份:2023
- 资助金额:
$ 27.29万 - 项目类别:
Studentship
Using novel modelling approaches to investigate the evolution of symmetry in early animals.
使用新颖的建模方法来研究早期动物的对称性进化。
- 批准号:
2842926 - 财政年份:2023
- 资助金额:
$ 27.29万 - 项目类别:
Studentship
Study of human late fetal lung tissue and 3D in vitro organoids to replace and reduce animals in lung developmental research
研究人类晚期胎儿肺组织和 3D 体外类器官在肺发育研究中替代和减少动物
- 批准号:
NC/X001644/1 - 财政年份:2023
- 资助金额:
$ 27.29万 - 项目类别:
Training Grant
RUI: Unilateral Lasing in Underwater Animals
RUI:水下动物的单侧激光攻击
- 批准号:
2337595 - 财政年份:2023
- 资助金额:
$ 27.29万 - 项目类别:
Continuing Grant
RUI:OSIB:The effects of high disease risk on uninfected animals
RUI:OSIB:高疾病风险对未感染动物的影响
- 批准号:
2232190 - 财政年份:2023
- 资助金额:
$ 27.29万 - 项目类别:
Continuing Grant
A method for identifying taxonomy of plants and animals in metagenomic samples
一种识别宏基因组样本中植物和动物分类的方法
- 批准号:
23K17514 - 财政年份:2023
- 资助金额:
$ 27.29万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)














{{item.name}}会员




